Editas Medicine, Inc. (EDIT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EDIT Revenue Growth
Revenue Breakdown (FY 2025)
EDIT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
EDIT Revenue Analysis (2014–2025)
As of May 8, 2026, Editas Medicine, Inc. (EDIT) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -151.6% year-over-year. The most recent quarter (Q4 2025) recorded $-15,779,000 in revenue, down 309.2% sequentially.
Looking at the longer-term picture, EDIT's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $90.7 million in 2020.
Revenue diversification analysis shows EDIT's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including CRSP (-88.9% YoY), BEAM (+108.0% YoY), and NTLA (+16.9% YoY), EDIT has underperformed the peer group in terms of revenue growth. Compare EDIT vs CRSP →
EDIT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EDITCurrent | $0 | -151.6% | - | - | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% |
EDIT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $0 | - |
| 2024 | $32.3M | -58.6% | $32.3M | 100.0% | $-251,152,000 | -777.2% |
| 2023 | $78.1M | +296.3% | $72.1M | 92.2% | $-169,181,000 | -216.6% |
| 2022 | $19.7M | -22.8% | $13.4M | 67.9% | $-225,950,000 | -1146.3% |
| 2021 | $25.5M | -71.8% | $20.5M | 80.2% | $-193,146,000 | -756.1% |
| 2020 | $90.7M | +341.9% | $-67,264,000 | -74.1% | $-134,840,000 | -148.6% |
| 2019 | $20.5M | -35.7% | $-76,367,000 | -372.0% | $-140,922,000 | -686.4% |
| 2018 | $31.9M | +132.6% | $-58,717,000 | -183.9% | $-113,727,000 | -356.1% |
| 2017 | $13.7M | +126.8% | $-69,431,000 | -505.8% | $-119,933,000 | -873.6% |
| 2016 | $6.1M | +271.6% | $-50,926,000 | -841.3% | $-97,188,000 | -1605.6% |
See EDIT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EDIT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EDIT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEDIT — Frequently Asked Questions
Quick answers to the most common questions about buying EDIT stock.
Is EDIT's revenue growth accelerating or slowing?
EDIT revenue declined -151.6% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is EDIT's long-term revenue growth rate?
Editas Medicine, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -151.6% is below this long-term average.
How is EDIT's revenue distributed by segment?
EDIT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.